Skip navigation

Ensure Program Integrity and Navigate Industry Uncertainty in a Highly Complex Market

August 20-21, 2019
  • Alexandria, VA

With evolving regulations impacting 340B programs, pharmaceutical companies are faced with uncertainty on how to strengthen program compliance and integrity. CBI’s 340B Manufacturer Summit breaks down and clarifies the impending regulations, provides strategies to develop comprehensive self-disclosure response and auditing processes, and establish best practices to collaborate with contract pharmacies and covered entities.

Along with convening 340B manufacturers, CBI’s Summit is also the only conference to convene manufacturers and covered entities within our Closed-Door Collaboration Summit to discuss innovative methods to work together under the 340B program.

Don’t miss out on the industry’s premiere event to propel collaborative initiatives, adhere to new and evolving regulatory guidance and mitigate risk within a highly complex market.

Critical Updates, Interactive Discussions
and Valuable Takeaways:

  • Gain key insights on 340B program developments and anticipated future rulings
  • Review the 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties (CMP) regulation
  • Operationalize the impact of HHS proposed reform and significance of the final rule
  • Uncover best practices for preventing revenue leakage Discuss covered entity and contract pharmacy challenges and strategies for collaboration
  • Hear relevant case studies on manufacturer successes

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of opportunities
to network with attendees.

President, Apexus

Outstanding conference for me as a new person to 340B.

Regional Account Manager, Helsinn Therapeutics

The CBI Conference was outstanding — very informative
and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson

As always, CBI delivered a conference filled with
quality content and subject matter experts
in the government programs field.

Director, Contracts & Pricing, Acorda Therapeutics, Inc.

340B Manufacturer Summit

Ensure Program Integrity and Navigate Industry Uncertainty in a Highly Complex Market

With evolving regulations impacting 340B programs, pharmaceutical companies are faced with uncertainty on how to strengthen program compliance and integrity. CBI’s 340B Manufacturer Summit breaks down and clarifies the impending regulations, provides strategies to develop comprehensive self-disclosure response and auditing processes, and establish best practices to collaborate with contract pharmacies and covered entities.

Along with convening 340B manufacturers, CBI’s Summit is also the only conference to convene manufacturers and covered entities within our Closed-Door Collaboration Summit to discuss innovative methods to work together under the 340B program.

Don’t miss out on the industry’s premiere event to propel collaborative initiatives, adhere to new and evolving regulatory guidance and mitigate risk within a highly complex market.

Critical Updates, Interactive Discussions
and Valuable Takeaways:

  • Gain key insights on 340B program developments and anticipated future rulings
  • Review the 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties (CMP) regulation
  • Operationalize the impact of HHS proposed reform and significance of the final rule
  • Uncover best practices for preventing revenue leakage Discuss covered entity and contract pharmacy challenges and strategies for collaboration
  • Hear relevant case studies on manufacturer successes

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of opportunities
to network with attendees.

President, Apexus

Outstanding conference for me as a new person to 340B.

Regional Account Manager, Helsinn Therapeutics

The CBI Conference was outstanding — very informative
and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson

As always, CBI delivered a conference filled with
quality content and subject matter experts
in the government programs field.

Director, Contracts & Pricing, Acorda Therapeutics, Inc.